Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone and vitamin B1, B6, and B12 in Post-COVID-19 syndrome
2022-001041-20Phase 3Completed
- Sponsor
- University Hospital Würzburg
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of prednisolone and Neurovit Forte in post-COVID syndrome (4 arms), sponsored by University Hospital Würzburg. Primary endpoint: Feasibility and acceptance of screening and recruitment. Started Jul 2022; status: completed.
02
Drugs
prednisoloneNeurovit Forte
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2022-001041-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001041-20.